GSK, its consumer health spin-off Haleon and Sanofi could be on the hook for billions…
Latest news
The 3rd TIGIT Axis Therapies Summit returns to unite large pharma, innovative biotechs and pioneering academics…
Novartis has secured its first approval in Europe for prostate cancer radioligand therapy Pluvicto, getting…
In the newest episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock welcomes Rebecca Guntern, vice…
Figures from the UK Office for National Statistics (ONS) have revealed that the number of…
The innovative Global Malnutrition Composite Score, approved by Centers for Medicare & Medicaid Services (CMS),…
Sanofi has paused recruitment in its international phase 3 trials of BTK inhibitor tolebrutinib for…
Cancer Research UK is working with global biopharma Sosei Heptares on a treatment they hope…
Merck & Co’s earlier efforts to find new therapies for Alzheimer’s disease resulted in failure,…
Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo’s TROP2-targeting…
More and more pharma companies are looking “beyond the pill” when it comes to providing…
Bristol-Myers Squibb has formed an R&D partnership with GentiBio, aimed at developing regulatory T cel…
More than 60 percent of all American adults take prescription drugs, amounting to approximately 131…
Bristol-Myers Squibb is on course to move its BCMA-targeting CAR-T therapy further up the treatment…
One of the digital health sector’s latest unicorn companies – Biofourmis – has upscaled its…
Social health—the dynamic, real-time action people take to find meaningful connections and share information that…
Healthcare technology firm Koneksa will carry out a study to evaluate whether digital biomarkers can…
UK-based Verona Pharma has scored a key win in a phase 3 trial of its…
EGFR inhibitors like AstraZeneca’s Tagrisso have been hugely successful in treating EGFR-positive lung cancer, but…
AI could address the most significant issue in drug discovery, finds Ben Hargreaves, and also…
Magnetic resonance imaging (MRI) technology specialist Bot Image has won FDA approval for its artificial…
Karuna Therapeutics has unveiled positive topline results from its phase 3 EMERGENT-2 trial evaluating the…
Pfizer’s reported interest in acquiring sickle cell disease specialist Global Blood Therapeutics (GBT) has been…
Over the last few years, our industry has become familiar with CDISC standards. This has largely…
Bayer has won a key FDA approval to extend the use of its prostate cancer…
A study of a mobile health app used to support patients hospitalised with heart failure…
The FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu as the first targeted therapy for…
Mark Doyle, co-founder of The Method and creator of the A Life in a Day…
Pfizer is on the brink of announcing a deal to buy Global Blood Therapeutics (GBT)…
The Inflation Reduction Act of 2022, a sweeping measure that now looks likely to be…
Sosei Heptares has taken another of its partnered G protein-coupled receptor (GPCR) programmes into mid-stage…
The largest pharma companies have all set themselves ambitious targets in recent years to improve…
Sanofi is making a €300 million investment in Chinese biotech Innovent as part of a…
Over the past 15 years, more than 60% of asset growth among the top 30…
Less than three years after being spun out of Oxford University, privately-held biotech MiroBio is…
Ten months after ChemoCentryx scored an unexpected FDA approval for autoimmune disease therapy Tavneos, Amgen…
Unlocking the secrets of the human genome has long been an ambitious pursuit for researchers…
Thousands of people in the UK will be screened for hepatitis C virus in a…
Pfizer has stopped development of a drug to treat cardiomyopathy caused by a rare form…
The European Commission has cleared AstraZeneca and Merck & Co’s Lynparza as an adjuvant or…
Across the economy, several industries have seen a significant increase in staff turnover due to…
Two phase 3 trials of Merck & Co’s Keytruda in metastatic castration-resistant prostate cancer (CRPC)…
According to the World Health Organization (WHO), approximately 296 million people globally live with hepatitis…
Heart failure Heart failure is one of the main causes of disability and mortality from…
In May, another amyloid targeting drug for Alzheimer’s disease – AC Immune and Roche’s crenezumab…
Gilead Sciences’ investment in oncology has started to provide a solid return, with sales of…
Ipsen and Servier’s hopes of extending the uses for chemotherapy drug Onivyde have been knocked…
We all know that real-world data (RWD) from electronic health records (EHR) could boost clinical…
The US FDA has approved a new biosimilar of Roche and Novartis’ blockbuster ophthalmology therapy…
Beijing biotech Sironax has closed a whopping $200 million second-round financing that shows investors still…